Cargando…
Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes
Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the ca...
Autores principales: | Lebedev, Timofey, Vagapova, Elmira, Spirin, Pavel, Rubtsov, Petr, Astashkova, Olga, Mikheeva, Alesya, Sorokin, Maxim, Vladimirova, Uliana, Suntsova, Maria, Konovalov, Dmitry, Roumiantsev, Alexander, Stocking, Carol, Buzdin, Anton, Prassolov, Vladimir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566230/ https://www.ncbi.nlm.nih.gov/pubmed/34556815 http://dx.doi.org/10.1038/s41388-021-02018-7 |
Ejemplares similares
-
Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling
por: Lebedev, Timofey, et al.
Publicado: (2022) -
Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas
por: Petrov, Ivan, et al.
Publicado: (2017) -
Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs
por: Vagapova, Elmira, et al.
Publicado: (2021) -
Two Receptors, Two Isoforms, Two Cancers: Comprehensive Analysis of KIT and TrkA Expression in Neuroblastoma and Acute Myeloid Leukemia
por: Lebedev, Timofey D., et al.
Publicado: (2019) -
Publisher Correction: Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis
por: Vagapova, Elmira R., et al.
Publicado: (2021)